RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 1.79 million. The enterprise value is 1.29 million.
| Market Cap | 1.79M | 
| Enterprise Value | 1.29M | 
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 | 
| Ex-Dividend Date | n/a | 
Share Statistics
RAMM Pharma has 119.39 million shares outstanding. The number of shares has increased by 0.01% in one year.
| Current Share Class | 119.39M | 
| Shares Outstanding | 119.39M | 
| Shares Change (YoY) | +0.01% | 
| Shares Change (QoQ) | n/a | 
| Owned by Insiders (%) | 31.43% | 
| Owned by Institutions (%) | 0.01% | 
| Float | 81.87M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 0.47 | 
| PB Ratio | 0.14 | 
| P/TBV Ratio | 0.14 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
| EV / Earnings | -0.10 | 
| EV / Sales | 0.34 | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | -0.80 | 
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.00.
| Current Ratio | 1.49 | 
| Quick Ratio | 0.82 | 
| Debt / Equity | 0.00 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | -0.02 | 
| Interest Coverage | -114.71 | 
Financial Efficiency
Return on equity (ROE) is -69.77% and return on invested capital (ROIC) is -22.63%.
| Return on Equity (ROE) | -69.77% | 
| Return on Assets (ROA) | -20.42% | 
| Return on Invested Capital (ROIC) | -22.63% | 
| Return on Capital Employed (ROCE) | -55.77% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | n/a | 
| Employee Count | n/a | 
| Asset Turnover | 0.18 | 
| Inventory Turnover | 1.34 | 
Taxes
In the past 12 months, RAMM Pharma has paid 12,666 in taxes.
| Income Tax | 12,666 | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has increased by +50.00% in the last 52 weeks. The beta is 0.04, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.04 | 
| 52-Week Price Change | +50.00% | 
| 50-Day Moving Average | 0.01 | 
| 200-Day Moving Average | 0.01 | 
| Relative Strength Index (RSI) | 52.50 | 
| Average Volume (20 Days) | 46,040 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 3.78 million and -13.24 million in losses. Loss per share was -0.11.
| Revenue | 3.78M | 
| Gross Profit | 897,058 | 
| Operating Income | -6.92M | 
| Pretax Income | -13.22M | 
| Net Income | -13.24M | 
| EBITDA | -6.37M | 
| EBIT | -6.92M | 
| Loss Per Share | -0.11 | 
Balance Sheet
The company has 529,411 in cash and 27,788 in debt, giving a net cash position of 501,623 or 0.00 per share.
| Cash & Cash Equivalents | 529,411 | 
| Total Debt | 27,788 | 
| Net Cash | 501,623 | 
| Net Cash Per Share | 0.00 | 
| Equity (Book Value) | 12.41M | 
| Book Value Per Share | 0.10 | 
| Working Capital | 1.23M | 
Cash Flow
In the last 12 months, operating cash flow was -1.58 million and capital expenditures -21,903, giving a free cash flow of -1.61 million.
| Operating Cash Flow | -1.58M | 
| Capital Expenditures | -21,903 | 
| Free Cash Flow | -1.61M | 
| FCF Per Share | -0.01 | 
Margins
| Gross Margin | 23.75% | 
| Operating Margin | -183.22% | 
| Pretax Margin | -350.16% | 
| Profit Margin | n/a | 
| EBITDA Margin | -168.79% | 
| EBIT Margin | -183.22% | 
| FCF Margin | n/a | 
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -0.01% | 
| Shareholder Yield | -0.01% | 
| Earnings Yield | -739.07% | 
| FCF Yield | -89.63% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
RAMM Pharma has an Altman Z-Score of -7.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.1 | 
| Piotroski F-Score | 3 |